natgillin/translations-raw huggingface dataset:
reliquefying boil-off gas generated in the LNG tank; and exchanging heat between the LNG to be supplied to the high-pressure gas injection engine and the boil-off gas generated in the LNG tank, wherein after the boil-off gas exchanges heat with the LNG, the LNG is supplied to the high-pressure gas injection engine, and the boil-off gas is reliquefied and then returned to the high-pressure gas injection engine. 
ukapljivanje isparenog plina stvorenog u spremniku LNG (1); te izmjenjivanje topline između LNG koji se treba dovesti u visokotlačni plinski injekcijski motor i isparenog plina stvorenog u spremniku LNG (1), naznačen time da nakon što ispareni plin izmjeni toplinu s LNG, navedeni LNG se dobavlja u visokotlačni plinski injekcijski motor, te se ispareni plin ukapljuje i potom vraća u visokotlačni plinski injekcijski motor.
stirring the suspension; filtering solids; 
(i) miješanje suspenzije;
Structure minutes (M + H)+ 
HPLC vrijeme retencije (u|(M+ H)" minutama)
providing feed water in need of remineralization, preparing a slurry comprising 0.05 to 40 wt.-% of micronized calcium carbonate based on the total weight of the slurry by mixing water and micronized calcium carbonate, wherein the micronized calcium carbonate has a particle size of 0.5 um to 100 um, the micronized calcium carbonate has a HCl insoluble content from 0.05 to 1.5 wt.-% based on the total weight of the micronized calcium carbonate, and the micronized calcium carbonate is ground calcium carbonate obtained from limestone, marble and/or chalk, calcium carbonate treated with a surface treatment agent, precipitated calcium carbonate, or any mixture thereof, and 
injektiranje plinovitog ugljik dioksida i mulja u ulaznu vodu, pri čemu mulj sadrži mikronizirani kalcij karbonat, gdje kalcij karbonat ima veličinu čestica od 0.1 do 100 µm. Postupak prema zahtjevu 1, pri čemu je koncentracija kalcij karbonata u mulju od 0.05 do 40 wt.%, od 1 do 25 wt.%, od 2 do 20 wt.-%, poželjno od 3 do 15 wt.-%, te najpoželjnije od 5 do 10 wt.-% zasnovano na ukupnoj masi mulji, ili je koncentracija kalcij karbonata u mulju od 10 do 40 wt.-%, od 15 do 30 wt.%, ili od 20 do 25 wt.-% zasnovano na ukupnoj masi mulja.
In larger mammals, e.g., humans, an indicated daily dosage is in the range from about 0.5 to about 5,000, preferably from about 1 mg to about 500 mg of a compound of the invention, conveniently administered, e.g., in divided doses up to four times a day or in sustained-release form. 
Kod većih sisavaca, npr. kod ljudi, indicirano dnevno doziranje je u rasponu od približno 0,5 do približno 5.000, ponajprije od približno 1 mg do približno 500 mg spojeva formula (I) i (Ia), koji se daju uobičajeno, npr. podijeljeni u doze sve do četiri puta dnevno ili u obliku trajnog oslobađanja.
The method according to claim 1, wherein said compound of formula (4): is prepared by the following step A3: 
NO, olJ/ O, priprema slijedećim korakom A3: pri čemu je spoj s formulom (3):
a light chain region comprising the amino acid sequence of SEQ ID NO:99; 
područje slabog lanca koje sadrži aminokiselinsku sekvencu SEQ ID NO:99;
The nucleic acid of claim 1, wherein the non-human MHC I polypeptide is a rodent MHC I polypeptide, and wherein the second nucleic acid sequence encodes transmembrane and cytoplasmic domains of the rodent MHC I polypeptide. 
Nukleinska kiselina prema zahtjevu 1, naznačena time, da ne-ljudski MHC-I-polipeptid je MHC-I-polipeptid glodavca, te time, da druga sekvenca nukleinske kiseline kodira transmembranske i citoplazmatske domene MHCI-polipeptida glodavca.
Hood for a cleanroom gown according to any one of the preceding claims, defining a mouth and nose area at the mouth and nose openings of the operator (10) and an eye and visor area at the eyes of the operator and the visor (30), wherein the at least one sealing device (66, 67, 68) prevents a fluid connection between the mouth and nose area and the eye and visor area. 
Kapuljača za ogrtač za čistu prostoriju prema bilo kojem od prethodnih zahtjeva, koja definira područje za usta i nos na otvorima za usta i nos operatera (10) i područje za oči i vizir kod očiju operatera i vizira (30), naznačena time da barem jedan uređaj za brtvljenje (66, 67, 68) sprječava protočnu vezu između područja usta i nosa i područja očiju 1 vizira.
represents a hydrogen atom or a C1-C6 alkyl group, and R5 represents a phenyl group, a thienyl group, a thiazolyl group, a pyridyl group, a naphthyl group, an indanyl group, a dihydrobenzofuranyl group, a benzodioxolyl group, a benzothiadiazolyl group, a benzothienyl group or a quinolinyl group, each of which may be substituted with 1 to 5 substituents selected from the group C [wherein the group C consists of a C1-C6 alkyl group, a halogen atom, a trifluoromethyl group, a C1-C6 alkoxy group, a trifluoromethoxy group, a nitro group, a cyano group, and a C2-C7 alkanoyl group], or a C2-C8 alkenyl group which may be substituted with a phenyl group(s)}. 
predstavlja fenilnu skupinu, tienil skupinu, tiazolil skupinu, piridil skupinu, naftil skupinu, indanil skupinu, dihidrobenzofuranil skupinu, benzodioksolil skupinu, benzotiadiazolil skupinu, benzotienil skupinu ili kinolinil skupinu, od kojih svaka može biti supstituirana sa 1 do 5 supstituenta odabranih iz skupine C [pri čemu skupina C sadrži C1-C6 alkilnu skupinu, atom halogena, trifluorometilnu skupinu, C1-C6 alkoksi skupinu, trifluorometoksi skupinu, nitro skupinu, cijano skupinu, te C2-C7 alkanoil skupinu], ili C2-C8 alkenil skupinu koja može biti supstituirana sa fenil skupinom(ama)}.
from 0.012 mg to 1.2 mg of zinc ions contained in fully water-soluble microgranules, 
učinkovita količina cinkovih iona koji su barem djelomično sadržani u mikrogranulama potpuno topljivim u vodi.
reducing the determined transmit power for each of a respective one of the uplink transmissions according to the priority of the component carriers given by the priority order on which the respective uplink transmission is to be transmitted, and 
Terminalni uređaj sukladno zahtjevu 1, naznačen time da kad se pluralitet PUSCH-ova konfigurira na pluralitetu prijenosnika komponenti, sekcija skaliranja skalira snagu za PUSCH prijenos smanjujući zbroj snaga pluraliteta PUSCH-ova.
in a third configuration pattern that is set in the third component carrier, at least an uplink communication subframe is set at a timing identical to that of an uplink communication subframe of the first configuration pattern; and the control section transmits, using the first component carrier, a response signal including error detection results corresponding to the data pieces respectively received using the first component carrier and the second component carrier, and transmits, using the third component carrier, a response signal including an error detection result corresponding to a data piece received using the third component carrier. 
HR P20181880 T1 pluralitet nosača komponenti nadalje uključuje trećeg nosača komponenti; treći obrazac konfiguracije okvira za treći nosač komponenenti definira vremena prijenosa jednog ili više podokvira uzlazne veze koji svi obuhvaćaju vremena prijenosa jednog ili više podokvira uzlazne veze definiranih prvim obrascem konfiguracije okvira; i signal odgovora nadalje označava rezultate otkrivanja pogrešaka od podataka silazne veze primljenih na trećem nosaču komponenti.
(A1f) a phenyl-substituted lower alkoxy group having a halogen-substituted lower alkoxy group(s) as a substituent(s) on a phenyl group), or a pyperazyl group represented by the general formula (A2): 
(A1f) fenil-supstituiranu skupinu niži alkoksi s halogen-supstituiranom skupinom (skupinama) niži alkil kao supstituentom (s) na fenilnoj skupini), ili piperazilnu skupinu prikazanu općom formulom (A2):
The mouthend pieces of the invention may include an optional "filter" tip, which is used to give the article the appearance of the conventional filtered cigarette. 
Komadi usnog dijela iz izuma mogu uključivati opcijski "filter"vrh koji se koristi da proizvodu da izgled konvencionalne cigarete sa filterom.
The method of claim 4, wherein the unscheduled media item is selected for output in said slot according to one or more constraints associated with one or more media items scheduled for output in at least one other programme slot. 
Postupak u skladu s patentnim zahtjevom 4, naznačen time što se neraspoređenu medijsku točku bira za izlaženje u navedenoj rupi prema jednom ili više ograničenja povezanih s jednom ili više medijskih točaka na rasporedu za izlaženje u najmanje jednoj drugoj rupi u programu.
a 9- or 10-membered fused bicyclic heteroaryl, having one heteroatom selected from the group consisting of N, O, and S, with a carbon as point of ring attachment, and optionally having up to four additional carbon ring atoms replaced with nitrogen, said fused bicyclic heteroaryl having not more than five heteroatoms; 
devetočlani ili desetočlani fuzionirani biciklični heteroaril, koji ima jedan heteroatom izabran iz grupe koja se sastoji od N, O, i S, sa ugljikom kao točkom prsten vezanja, i koji opcijski ima do četiri dodatna atoma ugljikovog prstena zamijenjena sa dušikom, spomenutim fuzioniranim bicikličnim heteroarilom koji ima ne više od 5 heteroatoma;
The effect of combined administration of a compound that inhibits serotonin reuptake and a 5-HT1A receptor antagonist has been evaluated in several studies (Inis et al. Eur. J. Pharmacol. 
Učinak kombinirane primjena spoja koji inhibira ponovnu pohranu serotonina i antagonista receptora 5-HT,a procjenjivan je u nekoliko studija (Innis 1 sur, Eur, J. Pharmacol.
The stripping composition of claim 1, wherein the water content in the composition is less than 0.5% by weight. 
Sastav za skidanje u skladu s bilo kojim od prethodnih zahtjeva, naznačen time da je sadržaj vode u sastavu manji od 0,5 mas.%.
For convenience, the reagents are named as derivatives of benzyl bromide (a-bromotoluene). 
Zbog prikladnosti, reagensi su imenovani kao derivati benzil bromida (a-bromotoluen).
An apparatus according to any one of claims 9 to 11, wherein the simulating (250) imitates ordinary behavior of mobile subscribers. 
Uređaj prema bilo kojem od zahtjeva 9 do 11, gdje simulacija (250) imitira uobičajeno ponašanje mobilnih pretplatnika.
The present invention relates to a novel universal organomineral and biostimulating fertilizer and to a method for the manufacture thereof. 
Predloženi izum odnosi se na područje kemijske tehnologije, posebno na novi postupak za proizvodnju novog univezralnog organsko-mineralnog i biostimulirajućeg gnojiva.
The antibody of claim 11 wherein the VL domain is humanised. The antibody of claim 14 wherein the VL domain comprises amino acids 21-127 of SEQ ID NO:25. 
Cc) -VL-domena je humanizirana; ili d) VL-domena je humanizirana, a sekvenca od ciljanog veznog elementa sadrži aminokiseline 21-127 od SEQ ID NO:25.
The method of claim 1, wherein the compound has the formula: 
18. Spoj prema zahtjevu 1, pri čemu je spoj:
The present invention also relates to processes for preparing the compounds of the invention as depicted in the following reaction schemes: 
U trećem obliku, predloženi izum se odnosi na postupke za pripravu spojeva formula (Ia), kako je gore prikazana, u slijedećim reakcijskim shemama:
System according to any of claims 1 to 3, wherein the side surface (13) of the use keys is situated in a different position from the side surface (15) of the change keys. 
Sustav prema patentnom zahtjevu 1. ili 2. 1li 3., kod kojeg je bočna površina (13) ključa smještena u različitom položaju od bočne površine (15) ključa za promjenu.
The composition or aerosol of claim 6, wherein the solution comprises levofloxacin and magnesium, has a concentration greater than about 50 mg/ml, has an osmolality from about 350 mOsmol/kg to about 750 mOsmol/kg, and has a pH from about 5.5 to about 6.5. 
Smjesa ili aerosol iz patentnog zahtjeva 6, pri čemu ovaj rastvor obuhvaća levofloksacin i magnezij, ima koncentraciju veću od oko 50 mg/ml, ima osmolarnost od oko 350 mOsmol/kg do oko 750 mOsmol/kg, i ima pH od oko 5,5 do oko 6.5.
The mice were given 10 mg/kg HMW Zn-HA s. c. daily and clinical data thereof were obtained from day 10 to day 28 and day 5 to day 22, respectively, after the EAE had been induced. 
Miševima je davano 10 mg/kg HMW Zn-HA s.c. dnevno i klinički podaci su dobiveni od 10. do 28. dana, odnosno 5. do 22. dana, nakon što je došlo do induciranja EAE.
A method for determining clotting time is described, of a fluid medium such as blood, using a low production cost device which can therefore be disposable. 
Mikrofluidički uređaj određivanja vremena koagulacije u fluidnom mediju, poput krvi ili plazme, gdje se navedeni uređaj sastoji od-
The pre-treatment may be recent (e.g. 
Prethodno liječenje može biti nedavno (na pr.
In another embodiment, the compound is selected from the group consisting of: 
Spoj prema zahtjevu 16, pri čemu je spoj izabran iz skupine koju čine:
Moreover, in step (3) a mixture comprising a sustained release polymer and a plasticizer for further enhancing film formation and its flexibility can be used. 
Osim toga, u koraku (3) može se upotrijebiti smjesa koja sadrži polimer za produljeno otpuštanje i plastifikator za daljnje olakšavanje formiranja filma i povećanje njegove fleksibilnost.
A liposome for use by topical administration in a method of medical treatment, which consists of dioleylphosphatidylethanolamine (DOPE), phosphatidylcholine, and cationic lipid, wherein the phosphatidylcholine comprises at least one unsaturated fatty acid chain containing a carbon-to-carbon double bond, and wherein the cationic lipid is O,O'-ditetradecanoyl-N-(a-trimethylammonioacetyl)diethanolamine chloride (DC-6-14). 
PATENTNI ZAHTJEVI Liposom, naznačen time, da se upotrebljava pomoću topikalne primjene u postupku medicinskog liječenja, te koji se sastoji od dioleilfosfatidiletanolamina (DOPE), fosfatidilkolina 1 kationskog lipida, pri čemu fosfatidilkolin obuhvaća najmanje jedan lanac nezasićene masne kiseline koji sadrži dvostruku vezu ugljik-ugljik, i pritom kationski lipid je O,O'-ditetradekanoil-N-(a-trimetilamonioacetil)dietanolaminklorid (DC-6-14).
A combination as defined in any one of claims 1 to 6 for use in the treatment of a disorder mediated by inappropriate PI3-kinase activity. 
Kombinacija u skladu s bilo kojim od patentnih zahtjeva 1 do 8, naznačena time što je namijenjena upotrebi u liječenju poremećaja uzrokovanog neodgovarajućom aktivnošću PI3-kinaze.
The antibody according to any of the preceding claims, said antibody being of IgG 2B class, and/or wherein said antibody comprises an amino acid sequence set forth in SEQ ID NO: 49. 
Antitijelo prema bilo kojem od prethodnih patentnih zahtjeva, pri čemu je navedeno antitijelo IgG 2B klase, i/ili gdje navedeno antitijelo sadrži aminokiselinsku sekvencu predstavljenu u SEQ ID NO: 49.
a capture tag agent of formula (III) Z—Y—XH (III) 
(a) sredstvo koje je oznaka za hvatanje formule (III)
dry grinding the almonds obtained in step a) such as to form an almond paste, preferably an almond paste having a volume weighed average particle diameter of below 30 µm, 
suho usitnjavanje badema dobivenih u koraku a) na način da se dobije pasta od badema, poželjno pasta od badema s prosječnim dijametrom čestica, vaganim po volumenu, ispod 30 um,
n is an integer selected from 1 and 2; 
n je cijeli broj odabran od 1 i 2;
Use according to claim 15 characterized in that said phospholipids have a higher than 97% degree of acetone insolubility. 
Uporaba prema zahtjevu 15 naznačena time što polarni fosfolipidi imaju stupanj netopljivosti u acetonu veći od
The human engineered DKK-1 antibody of any one of Clauses 3 to 9 or Clause 11, wherein the human engineered DKK-1 antibody comprises a heavy chain wherein the heavy chain comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 17 and SEQ ID NO: 18. 
Ljudsko konstruirano protutijelo protiv DKK-1, namijenjeno upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što ljudsko konstruirano protutijelo protiv DKK-I sadrži teški lanac koji ima aminokiselinski slijed sa SEQ ID NO: 18 1 laki lanac koji ima aminokiselinski slijed sa SEQ ID NO: 20.
deprotecting the G group of the compound synthesized in step (i) under suitable conditions to form a_compound of Formula (IV) or a pharmaceutically acceptable salt thereof. 
7. Postupak za pripremu spoja formule ili njegove farmaceutski prihvatljive soli, koji sadrži korake: i) reagiranja spoja 6: sa spojem 7a: da se formira spoj &a:
Also of note is a method for controlling an invertebrate pest comprising contacting the invertebrate pest or its environment with a biologically effective amount of a compound of the present invention or with a composition comprising a biologically effective amount of a compound of the present invention. 
Metoda za suzbijanje štetnog beskralješnjaka, naznačena time, što se sastoji od dovođenja u kontakt štetnog beskralježnjaka ili njegove okoline sa smjesom iz bilo kojeg od Zahtjeva 9 do 16, uz uvjet da metoda nije metoda liječenja čovjeka ili životinje putem terapije.
an electric heater having a body comprising at least one sidewall that defines an interior void, at least one inner surface, at least one outer surface, and a plurality of apertures through the at least one sidewall, the electric heater comprising an electrically resistive material contained within a heat diffusing material; 
električni grijač (14), koji ima tijelo, koje obuhvaća najmanje jednu bočnu stranicu s unutrašnjim šupljim prostorom (70), najmanje jednu unutrašnju površinu, najmanje jednu vanjsku površinu i veliki broj otvora u najmanje jednoj bočnoj stranici, pri čemu električni grijač obuhvaća električno otporni materijal, koji je sadržan u materijalu za difuziju topline;
An oral formulation in tablet form according to claim 4, wherein the stabilizer is 0.01% to 0.5% weight percent sodium bisulfite. 
Oralna formulacija u obliku tablete u skladu s patentnim zahtjevom 4, naznačena time što je stabilizator 0,01% do 0,5%, težinski, natrijev bisulfit.
A method for treating or preventing a cancer in a patient comprising administering to the patient a therapeutically effective amount of the pharmaceutical composition of any one of the preceding claims. The method according to claim 14, wherein the pharmaceutical composition is an anti-cancer vaccine. 
Terapijski učinkovita količina farmaceutskog sastava iz bilo kojeg od prethodnih zahtjeva za uporabu u liječenju ili sprječavanju karcinoma kod pacijenata, Farmaceutski sastav za uporabu prema zahtjevu 11, naime kao cjepivo protiv karcinoma.
The peptide according to Claim 1, wherein said peptide includes non-peptide bonds. 
Peptid u skladu s patentnim zahtjevom 1, pri čemu navedeni peptid uključuje nepeptidne veze.
Thus, in one aspect, a crystalline hydrochloride salt of the compound of formula I is characterized by a powder x-ray diffraction pattern in which the peak positions are substantially in accordance with those shown in Figure 1 . 
Spoj u obliku kristalne soli u skladu s patentnim zahtjevom 1, naznačen time, da je taj spoj u obliku kristalne soli kristalna klorovodična sol.
Free base 
Slobodna baza ZN
The shoe 10 comprises a breathable and waterproof sole 11, described hereinafter, and an assembly 12 that is associated with it in an upward region and is constituted by an external breathable upper 13, an internal lining 14 and, between them, a breathable and waterproof membrane 15, which is made for example of a material such as Gore-Tex® or the like. 
Cipela 10 sadrži prozračan i vodootporni potplat 11, opisan u tekstu što slijedi, i sklop 12 koji je s prethodnim povezan u gornjem dijelu, a čine ga vanjsko prozračno gornjište 13 i unutarnja podstava 14, a između njih se nalazi prozračna i vodootporna membrana 15, koja je izrađena primjerice od Gore-Texa? ili sličnog materijala. p
A retention groove is then formed in the dentin if needed to maintain the restoration on the tooth. 
Ako je za rekonstrukciju zuba potrebno, oblikovan je žlijeb u dentinu.
A glucocorticoid contained in a delayed-release dosage form for use according to any one of the previous claims, wherein said patient has or has not been treated previously with a oral immediate release glucocorticoid, and/or a NSAID, a DMARD, a TNFa inhibitor, an IL-1 inhibitor, an IL-6 inhibitor, an analgetic agent, or combinations thereof. 
Glukokortikoid sadržan u obliku doziranja s odgođenim otpuštanjem za uporabu prema bilo kojem od prethodnih patentnih zahtjeva, pri čemu je navedeni bolesnik bio ili nije bio prethodno liječen oralnim glukokortikoidima s izravnim otpuštanjem, i/ili NSAID-om, DMARD-om, inhibitorom TNFqa, inhibitorom IL-1, inhibitorom IL-6, analgetikom, ili kombinacijama navedenog.
Re is -H, a linear, branched or cyclic alkyl, alkenyl or alkynyl having 1 to 10 carbon atoms or -(CH2-CH2-O)n-Rk, wherein Rk is a -H, a linear, branched cyclic alkyl having 1 to 6 carbon atoms, optionally bearing a secondary amino (e.g., - NHR101) or tertiary amino (-NR101R102) group or a 5- or 6-membered nitrogen containing heterocycle, such as piperidine or morpholine, wherein R101 and R102 are each independently a linear, branched, or cyclic alkyl, alkenyl or alkynyl having 1 to 10 carbon atoms; 
je Re -H, linearni, razgranati ili ciklični alkil, alkenil ili alkinil koji ima 1 do 10 ugljikovih atoma ili -(CH2-CH2-O)n-Rk, pri čemu Rk je -H, linearni, razgranati ciklični alkil koji ima 1 do 6 ugljikovih atoma, koji izborno nosi sekundarnu amino (npr., -NHR101) ili tercijarnu amino (-NR101R102) skupinu ili 5-člani ili 6-člani dušik koji ima heterocikl, kao što je piperidin ili morfolin, pri čemu su R101 i R102 svaki neovisno linearni, razgranati ili ciklični alkil, alkenil ili alkinil koji ima 1 do 10 ugljikovih atoma;
The characteristics of these oligo- and polysaccharides are dependent on, for instance, the saccharide composition, the bonds between the saccharides and the degree of polymerisation (DP). 
Svojstva tih oligosaharida i polisaharida ovise, na primjer, o sastavu saharida, vezama između saharida i stupnju polimerizacije (DP, degree of polymerisation).
With the size of the constituents of the waste stream reduced, the conveying of the waste stream to the material classification subsystem can further include passing the waste stream through a set of separators. 
Postupak u skladu s patentnim zahtjevom 1, naznačen time, da obrada toka komunalnog krutog otpada uključuje usitnjavanje barem dijela toka otpada do prosječne veličine manje od 2,54 em (1 palac).
We have now surprisingly discovered that certain novel cis-isomeric derivatives of 4-phenyl-l,2,3,4-tetrahydro-l-naphthalenamine are useful as antidepressant agents. 
Mi smo sada neočekivano otkrili da su izvjesni cis-izomerni derivati 4-fenil-1,2,3,4-tetrahidro-1-naftalinamina, dobiveni postupkom iz sadašnjeg izuma, korisna antidepresivna sredstva.
The fusion protein of any one of the preceding aspects, wherein said immunoglobulin molecule comprises a modification reducing binding affinity of the immunoglobulin molecule to an Fc receptor as compared to a corresponding immunoglobulin molecule without said modification. 
Fuzijski protein prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time, da spomenuta molekula imunoglobulina obuhvaća modifikaciju koja smanjuje afinitet vezivanja molekule imunoglobulina na Fc-receptor u usporedbi s odgovarajućom molekulom imunoglobulina bez spomenute modifikacije.
A process for preparing the compound of claim 1, comprising: coupling compound (1) and compound (2) under amide bond-forming conditions and deprotecting the product to form compound (3): 
(a) sprezanje spoja (1) i spoja (2) u uvjetima za nastanak amidne voze te skidanje zaštite, čime se dobiva spoj (3): m").
Vaccine according to any one of claims 1 to 6, characterised in that the at least two fragments of PCSK9 are coupled to a pharmaceutically acceptable carrier, preferably KLH (Keyhole limpet hemocyanin). 
Cjepivo prema bilo kojem od zahtjeva 1 do 5, naznačeno time, da su najmanje dva fragmenta od PCSK9 spojena na farmaceutski prihvatljiv nosač, poželjno na KLH (Keyhole Limpet Hemocyanin).